Drug Profile
Research programme: joint and arthritic disorder therapeutics - Seikagaku Corporation
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Seikagaku Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arthritis; Joint disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Arthritis in Japan
- 04 Nov 2017 No recent reports of development identified for preclinical development in Joint-disorders in Japan